Femoral BMD Change Following Cemented or Cementless Total Knee Arthroplasty

NCT ID: NCT06733597

Last Updated: 2025-03-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-06

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine femur bone mineral density (BMD) change before and after surgery in patients receiving cemented or cementless total knee arthroplasty (TKA). performed with manual or robotic methods. 100 participants will be enrolled and can expect to be on study for up to 14 months.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It has previously been reported that total knee arthroplasty (TKA) causes major femur bone loss (\~18% within 1 year). Prior studies did not examine different surgical methods, such as the use of cement or robotics, in TKA. The investigators hypothesize that previously reported differences in distal femur BMD change following TKA exist between patients receiving cemented vs. cementless prostheses.

Specific Aim 1: In the entire study cohort, our primary endpoint is to estimate percent BMD change 12 months after TKA at the distal femur 25% region of interest (ROI).

Specific Aim 1a: To compare percent BMD change 12 months after TKA at the distal femur 25% ROI in cemented vs uncemented implants.

Specific Aim 1b: To compare percent BMD change 12 months after TKA at the distal femur 25% ROI in those receiving robotic vs manual implants.

Specific Aim 2: In the entire study cohort, our secondary endpoints are to estimate percent BMD change 12 months after TKA at a.) the distal femur 15% ROI and b.) a proximal tibial ROI Specific Aim 2a: To compare percent BMD change 12 months after TKA at the distal femur 15% ROI and proximal tibial ROI in cemented vs uncemented implants.

Specific Aim 2b: To compare percent BMD change 12 months after TKA at the distal femur 15% ROI and proximal tibial ROI in in those receiving robotic vs manual implants.

Exploratory Aim 1: Compare patient reported pain and function at 2 weeks, 3 and 12 months:

1. in those receiving cemented and cementless implants.
2. in those receiving robotic vs manual implants.

Exploratory Aim 2: Evaluate leg lean mass change as measured by DXA and BIS at 2 weeks, 3 and 12 months over time.

1. In the entire cohort
2. in those receiving cemented and cementless implants.
3. in those receiving robotic vs manual implants.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Arthropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cemented and Manual

Group Type ACTIVE_COMPARATOR

Cement

Intervention Type PROCEDURE

The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.

Manual Surgery

Intervention Type PROCEDURE

The manual approach is the surgeon determining prosthetic placement using techniques developed during training.

Cemented and Robotic

Group Type ACTIVE_COMPARATOR

Cement

Intervention Type PROCEDURE

The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.

Robotic Surgery

Intervention Type PROCEDURE

The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.

Cementless and Manual

Group Type ACTIVE_COMPARATOR

Cementless

Intervention Type OTHER

The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.

Manual Surgery

Intervention Type PROCEDURE

The manual approach is the surgeon determining prosthetic placement using techniques developed during training.

Cementless and Robotic

Group Type ACTIVE_COMPARATOR

Cementless

Intervention Type OTHER

The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.

Robotic Surgery

Intervention Type PROCEDURE

The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cement

The cemented approach includes inserting cement into the femur and tibia prior to setting the prosthetic.

Intervention Type PROCEDURE

Cementless

The non-cement approach uses a different type of prosthetic that is placed tight against the bone and requires no other fixation material.

Intervention Type OTHER

Manual Surgery

The manual approach is the surgeon determining prosthetic placement using techniques developed during training.

Intervention Type PROCEDURE

Robotic Surgery

The haptic robotic assisted approach uses a computer and robot to determine specific placement of the prosthetic.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients age greater than or equal to 55 years undergoing TKA with no prior total joint arthroplasty on the surgical side
* Normal BMD or osteopenia with Fracture Risk Assessment Tool (FRAX) not meeting Bone Health and Osteoporosis Foundation (BHOF) treatment recommendations, i.e., 10-year major osteoporotic fracture risk greater then or equal to 20 percent or hip fracture risk greater than or equal to 3 percent.

Exclusion Criteria

* Known clinical osteoporosis defined as any one of the following:

* Hip or spine T-score less than or equal to -2.5
* History of low trauma fracture after age 50
* FRAX fracture risk calculation greater than or equal to 20 percent for major osteoporotic fracture or greater than or equal to 3 percent for hip fracture
* Prior or current use of osteoporosis medications
* Current use of systemic glucocorticoids or bone-active medications
* Rheumatoid arthritis
* Laboratory abnormalities that in the opinion of study investigators may impact bone mineral density; including calcium, creatinine, albumin and parathyroid hormone (PTH)
* 25(OH)D less than 20 ng/mL
* Not suitable for study participation due to other reasons at the investigator's discretion
Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Wisconsin, Madison

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brian Nickel, MD

Role: PRINCIPAL_INVESTIGATOR

UW School of Medicine and Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UW School of Medicine and Public Health

Madison, Wisconsin, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Osteoporosis Clinical Research Program

Role: CONTACT

608-265-6410

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Protocol Version 10/31/24

Identifier Type: OTHER

Identifier Source: secondary_id

A536110

Identifier Type: OTHER

Identifier Source: secondary_id

2024-0197

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.